| IMIDomics–Pritzker Organization: investment, 202107 financing round Series A totalling $16.5m incl co-investor The Pritzker Organization |
2021-07-27 |
| IMIDomics–SEVERAL: investment, 202107 financing round Series A $16.5m led by DNS Capital |
2021-07-27 |
| IMIDomics–Tao Capital: investment, 202107 financing round Series A totalling $16.5m incl co-investor Tao Capital |
2021-07-27 |
| Axa–SEVERAL: investment, 202107 raising of €1.9b equity by AXA IM Alts to invest in European Life Sciences primarily via Kadans Science Partner |
2021-07-26 |
| Nerre Therapeutics–Columbus Venture Partners: investment, 202107 financing round Series B2 totalling £20m incl new + lead investor Columbus VP |
2021-07-07 |
| Nerre Therapeutics–SEVERAL: investment, 202107 financing round Series B2 £20m led by Columbus Venture Partners |
2021-07-07 |
| ViveBiotech–Image Box: public relations, 202106 service existent by Image Box Communications |
2021-06-04 |
| Highlight Therapeutics–Droia Ventures: investment, 202105 existent portfolio company of Droia |
2021-05-17 |
| Cytoki Pharma–SEVERAL: investment, 202105 financing round Series A $45m led by existing investor Lundbeckfonden Emerge |
2021-05-05 |
| Adcendo–SEVERAL: investment, 202104 financing round Series A €51m co-led by Novo Seeds + Ysios Capital |
2021-04-29 |
| Adcendo–Ysios Capital: investment, 202104 financing round Series A totalling €51m incl co-lead investor Ysios Capital |
2021-04-29 |
| Synendos Therapeutics–Ysios Capital: investment, 202104 investment by new investor Ysios Capital extends financing round Series A to CHF24m |
2021-04-20 |
| Inbrain Neuroelectronics–SEVERAL: investment, 202103 financing round Series A €14.35m led by Asabys Partners incl follow-on from ICF VTII |
2021-03-26 |
| Aura Biosciences–SEVERAL: investment, 202103 financing round $80m led by Matrix Capital Management + Surveyor Capital |
2021-03-22 |
| Almirall–MC2 Therapeutics: Wynzora Cream, 202102– license excl to commercialise Wynzora Cream for plaque psoriasis in Europe for Almirall |
2021-02-17 |
| MedLumics–Andera Partners: investment, 202102 financing round totalling €18m incl existing investor Andera Partners |
2021-02-10 |
| MedLumics–Asabys Partners: investment, 202102 financing round totalling €18m incl new + lead investor Asabys Partners |
2021-02-10 |
| MedLumics–Eurazeo: investment, 202102 financing round totalling €18m incl new investor Kurma Partners |
2021-02-10 |
| MedLumics–Innogest SGR: investment, 202102 financing round totalling €18m incl existing investor Innogest Capital II |
2021-02-10 |
| MedLumics–la Caixa: investment, 202102 financing round totalling €18m incl existing investor Caixa Capital Risc |
2021-02-10 |
| MedLumics–Optimum Strategic Communications: public relations, 202102 service existent by Optimum |
2021-02-10 |
| MedLumics–SEVERAL: investment, 202102 financing round €18m led by Asabys Partners |
2021-02-10 |
| MedLumics–Spain (govt): investment, 202102 financing round totalling €18m incl new investor CDTI Innvierte Economía |
2021-02-10 |
| MedLumics–VI Partners: investment, 202102 financing round totalling €18m incl new investor VI Partners Swiss Innovation |
2021-02-10 |
| Minoryx–Image Box: public relations, 202101 service existent by Image Box Communications |
2021-01-26 |
| CorWave–SEVERAL: investment, 202101 financing round Series C €35m led by new investor EIC Fund |
2021-01-06 |
| CorWave–Ysios Capital: investment, 202101 financing round Series C totalling €35m incl existing + co-investor Ysios Capital |
2021-01-06 |
| ECBF–SEVERAL: investment, 202012 2nd closing with additional €93m from new investors bringing total to €175m |
2020-12-15 |
| Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED |
2020-12-01 |
| Sarcura–Axilium Holding: investment, 202011 seed financing round totalling €2.5m incl investor Axilium Capital |
2020-11-19 |
| Sarcura–Nina Capital: investment, 202011 seed financing round totalling €2.5m incl investor Nina Capital |
2020-11-19 |
| Sarcura–SEVERAL: investment, 202011 seed financing round €2.5m (not specified whether this amount incl AWS Seed grant) |
2020-11-19 |
| Sidekick Health–SEVERAL: investment, 202010 financing round Series A $20m led by Wellington Partners + Asabys Partners |
2020-10-28 |
| SparingVision–SEVERAL: investment, 202010 financing round €44.5m led by 4BIO Capital + UPMC Enterprises |
2020-10-21 |
| SparingVision–Ysios Capital: investment, 202010 financing round totalling €44.5m incl new + co-investor Ysios Capital |
2020-10-21 |
| Prolytic–Kymos: investment, 202009 strategic merger of Polytic GmbH + Kymos SL |
2020-09-28 |
| Galecto–SEVERAL: investment, 202009 financing round $64m led by Soleus + co-lead by Eir Ventures |
2020-09-25 |
| Galecto–Ysios Capital: investment, 202009 financing round totalling $64m incl existing + co-investor Ysios Capital |
2020-09-25 |
| Lava Therapeutics–SEVERAL: investment, 202009 financing round Series C $83m co-led by Novo Ventures + Sanofi Ventures |
2020-09-17 |
| Lava Therapeutics–Ysios Capital: investment, 202009 financing round Series C totalling $83m incl new + co-investor Ysios Capital |
2020-09-17 |
| Algenex–SEVERAL: investment, 202009 private financing round €7.4m led by MasterLux + incl new investor Columbuus Life Science Fund II |
2020-09-08 |
| IntegraGen–OncoDNA: investment, 202007–202011 acquisition public offer at €2.2/share valuing IntegraGen at €14.5m |
2020-07-08 |
| VarmX–SEVERAL: investment, 202007 financing round Series B €32m co-led by Ysios Capital + INKEF Capital |
2020-07-08 |
| Ona Therapeutics–Alta Life Sciences: investment, 202006 financing round Series A totalling €30m incl new investor Alta Life Sciences |
2020-06-16 |
| Ona Therapeutics–Asabys Partners: investment, 202006 financing round Series A totalling €30m incl existing investor Sabadell Asabys |
2020-06-16 |
| Ona Therapeutics–France (govt): investment, 202006 financing round Series A totalling €30m incl new investor Bpifrance InnoBio 2 |
2020-06-16 |
| Ona Therapeutics–Fund+: investment, 202006 financing round Series A totalling €30m incl new investor Fund+ |
2020-06-16 |
| Ona Therapeutics–SEVERAL: investment, 202006 financing round Series A €30m |
2020-06-16 |
| Ona Therapeutics–Ysios Capital: investment, 202006 financing round Series A totalling €30m incl new investor Ysios Capital |
2020-06-16 |
| Ysios Capital–SEVERAL: investment, 202006 first closing €155m of Ysios BioFund III with target size of €200m |
2020-06-10 |
| Artax Biopharma–Columbus Venture Partners: investment, 202006 financing round Series B Extension incl new + lead investor Columbus Venture Partners |
2020-06-04 |
| Artax Biopharma–SEVERAL: investment, 202006 financing round Series B Extension led by new investor Columbus Venture Partners |
2020-06-04 |
| Inbrain Neuroelectronics–SEVERAL: investment, 202006 seed financing round led by Sabadell-Asabys + Alta Life Sciences |
2020-06-01 |
| Accure Therapeutics–SEVERAL: investment, 202005 financing round Series A €7.6m led by Alta Life Sciences with support from CDTI |
2020-05-26 |
| FairJourney Biologics–GHO Capital: investment, 202005 investment by GHO Capital to facilitate acquisition of Iontas by FJB |
2020-05-13 |
| Iontas–FairJourney Biologics: investment, 202005 acquisition of Iontas by FJB facilitaed by investment from GHO Capital |
2020-05-13 |
| LNC Therapeutics–Univ Valencia: microbiomic treatment, 202004– license ww excl for patent on Christensenella therapeutics for mood disorders |
2020-04-15 |
| Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS |
2020-03-10 |
| Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF |
2020-03-10 |
| Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical |
2020-03-10 |
| Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF |
2020-03-10 |
| OncoDNA–Belgium (govt): investment, 202002 financing round Series B totalling €19m incl significant support from co-investor SFPI-FPIM |
2020-02-14 |
| OncoDNA–SEVERAL: investment, 202002 financing round Series B €19m co-led by Vesalius Biocapital III + Swisscanto Invest |
2020-02-14 |
| OncoDNA–Vesalius Biocapital: investment, 202002 financing round Series B totalling €19m incl co-lead investor Vesalius Biocapital III |
2020-02-14 |
| OncoDNA–Zürcher Kantonalbank: investment, 202002 financing round Series B totalling €19m incl co-lead investor Swisscanto Invest by ZKB |
2020-02-14 |
| Stalicla–SEVERAL: investment, 202002 financing round Series A 2nd closing of CHF7.7m ($8m) bringing total raised to $18.4m |
2020-02-03 |
| Almirall–23andMe: therapeutic antibodies, 202001– license ww to bispecific MAb blocking all 3 isoforms of IL-36 |
2020-01-09 |
| Almirall–WuXi PharmaTech: therapeutic antibodies, 202001– collab strategic RnD bispecific Abs for dermatology using WuXiBody antibody technology |
2020-01-09 |
| Riemser–Esteve: investment, 202001– acquisition €na of Riemser from Ardian by Esteve |
2020-01-08 |
| TherVacB project–EU (govt): grant, 202001–202412 Horizon 2020 grant €10.4m for development of therapeutic Hepatitis B vaccine |
2020-01-01 |
| Elypta–Nina Capital: investment, 201912 late seed financing round totalling €6.1m incl co-investor Nina Capital |
2019-12-01 |
| Elypta–SEVERAL: investment, 201912 late seed financing round €6.1m co-led by Industrifonden + Sciety |
2019-12-01 |
| ECBF–EU (govt): investment, 201911–202010 first closing totalling €82m incl cornerstone investor EIB that has committed up to €100m |
2019-11-29 |
| ECBF–SEVERAL: investment, 201911–202010 first closing €82m from cornerstone investor EIB + 3 private investors + target size of €250m |
2019-11-29 |
| Grifols–Shanghai RAAS: investment, 201911c acquisition 45% share (40% of voting rights) in Grifols Diagnostic Solutions via share swap |
2019-11-13 |
| Grifols–Shanghai RAAS: plasma products + diagnostics, 201911c– strategic alliance in China incl share swap |
2019-11-13 |
| Shanghai RAAS–Grifols: investment, 201911c acquisition 26.2% share in Shanghai RAAS via share swap as part of strategic alliance |
2019-11-13 |
| Expedeon–Abcam: investment, 201911– acquisition €120m cash of immunology + proteomics business of Expedeon by Abcam ANNOUNCED |
2019-11-11 |
| i-Dositecno–SP Industries: investment, 201910 acquisition of assets of i-Dositecno by SP Industries |
2019-10-28 |
| Sofinnova–SEVERAL: investment, 201910 closing €333m of Sofinnova Capital IX fund |
2019-10-17 |
| SP Industries–i-Dositecno: filling solutions, 201908– collab product integration to offer complete aseptic vial/syringe fill-finish lines |
2019-08-13 |
| Infarco–Keensight Capital: investment, 201907 acquisition of Infarco’s majority stake in 3P Biopharmaceuticals by Keensight |
2019-07-23 |
| Medicxi Ventures–JnJ: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–Novartis: investment, 201907 closing totalling €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| Medicxi Ventures–SEVERAL: investment, 201907 closing €400m of Medicxi III fund incl cornerstone investors + Novartis + JJDC |
2019-07-19 |
| AM-Pharma–Eurazeo: investment, 201907 financing round totalling €116m incl existing + co-investor Kurma Partners |
2019-07-16 |
| AM-Pharma–SEVERAL: investment, 201907 financing round €116m co-led by LSP + Andera Partners |
2019-07-16 |
| Sanifit–Alta Life Sciences: investment, 201906 financing round Series D totalling €55.2m incl new + co-investor Alta Life Sciences |
2019-06-26 |
| Sanifit–Andera Partners: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Andera Partners |
2019-06-26 |
| Sanifit–Columbus Venture Partners: investment, 201906 financing round Series D totalling €55.2m incl new + co-investor Columbus Venture Partners |
2019-06-26 |
| Sanifit–Consilium: public relations, 201906 service existent by CSC |
2019-06-26 |
| Sanifit–Forbion: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Forbion Capital Partners |
2019-06-26 |
| Sanifit–Gilde Investment: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Gilde Healthcare |
2019-06-26 |
| Sanifit–HealthEquity: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor HealthEquity |
2019-06-26 |
| Sanifit–la Caixa: investment, 201906 financing round Series D totalling €55.2m incl existing + lead investor Caixa Capital Risc |
2019-06-26 |
| Sanifit–Lundbeck: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Lundbeckfonden Ventures |
2019-06-26 |
| Sanifit–SEVERAL: investment, 201906 financing round Series D €55.2m led by Caixa Capital Risc |
2019-06-26 |
| Sanifit–SEVERAL: investment, 201906c capitalisation of €17m of convertible bonds |
2019-06-26 |
| Sanifit–Ysios Capital: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Ysios Capital |
2019-06-26 |
| Ona Therapeutics–Asabys Partners: investment, 201905 seed financing €1.5m from Sabadell Asabys Fund |
2019-05-21 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo.svg){kind=logo}
1 2 3 4 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
